Researchers at Northwestern University have developed protein-like polymers (PLPs) called HYDRACs that can target and degrade "undruggable" cancer-driving proteins like MYC and KRAS by marking them for cellular degradation machinery. This breakthrough offers a new approach to treating cancers driven by these notoriously difficult-to-target proteins, potentially expanding treatment options beyond current small molecule drugs.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



